Why Excipient Suppliers Should Dump Most DMFs Prior To May Deadline
Executive Summary
An excipient trade group said that converting paper drug master files to electronic DMFs is fraught with challenges and suggested some alternatives to ease the path for communicating proprietary information to US FDA. Agency guidance has set a May 5 deadline for conversion to eDMFs.
You may also be interested in...
Manufacturing Regulatory Updates In Brief
FDA's “Wayback” archive; EMA's whistleblower policy; IPRF's drug ID plan; reprieve for DMF holders; investigational compounding; PK/PD for kids; ISPE on quality culture; PDA on quality risks.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.